In NSCLC xenograft models, the combination of ceralasertib (AZD6738) and cisplatin resulted in near-complete resolution of ATM-deficient NSCLC tumors, suggesting that ATM-deficient tumors are particularly sensitized to ATR inhibition in combination with platinum.3 The gene discussed is ATR; the disease is non-small cell lung carcinoma.